CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 12 target
Drug / intervention
biotindietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03034707
NCT03034707N/ACompleted

Interference of Biotin Supplementation in Biotin-streptavidin Platforms for Hormone Testing

University of Minnesota·interventional·Posted Jan 27, 2017·Updated Apr 19, 2019

In Brief

A clinical study evaluating biotin for Thoracic Diseases and Parathyroid Diseases. Completed, enrolled 12 participants.

Detailed Summary

The B vitamin biotin is widely available as an over the counter supplement, often advertised and used to promote health of hair, skin and nails. Commercially available over the counter biotin supplements contain dose ranges up to 10 mg/day (ie 333 times higher than the recommended dietary allowance). The biotin molecule is also sometimes used as part of the lab technology to measure hormone and protein levels in the blood. It is possible that high doses of ingested biotin may interfere with accurate hormone or protein measurement using biotin related in vitro measurement systems. Such interference, if present, could lead to misdiagnosis. The study will analyze laboratory levels obtained with streptavidin-biotin assay systems while ingesting biotin in currently available high dose supplements. The data will be compared to measurements obtained prior to and one week after stopping the biotin supplement.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--

Timeline

N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJan 27, 2017
Enrollment StartApr 1, 2016
Primary CompletionOct 1, 2016
Study CompletionDec 31, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 9.4 years ago

Interventions

biotindietary